Diagnosis and treatment of iron overload in paediatric patients on chronic haemodialysis.
In this study the incidence and contributing factors of iron overload in paediatric patients treated with intermittent haemodialysis were evaluated. Particular attention was given to the diagnostic value of serum ferritin in the assessment of body iron stores in patients with hepatocellular damage. The results of treatment of secondary haemosiderosis with desferrioxamine (DFO) are reported. Serum ferritin levels were measured in 18 children and adolescents undergoing long-term haemodialysis; 8 of these had biochemical evidence of hepatocellular damage. In all patients a good correlation was found between serum ferritin levels and the amount of iron stored in the reticuloendothelial system. Six patients developed iron overload. Patients with secondary haemosiderosis were younger at the start of haemodialysis and received significantly more blood. Although not significant, more patients with haemochromatosis-associated alleles and bilateral nephrectomy had iron overload, and the duration of dialysis was obviously longer for overload patients (40 months versus 26 months). The patients with iron overload were treated with DFO. The data from all patients showed that DFO was ineffective when administered at a dose of 25 mg/kg during dialysis and that in individual patients changes in serum ferritin correlated with changes in the amount of blood transfusions administered.
Eijgenraam
F J
FJ
Department of Haemodialysis, University Children's Hospital, Utrecht, The Netherlands.
Donckerwolcke
R A
RA
van Dijken
P J
PJ
D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003676:Deferoxamine / Q000627:therapeutic use; D005260:Female; D005293:Ferritins / Q000378:metabolism; D006680:HLA Antigens; D006432:Hemochromatosis / Q000209:etiology / Q000276:immunology; D006486:Hemosiderosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D007501:Iron / Q000378:metabolism*; D008099:Liver / Q000503:physiopathology; D008297:Male; D006435:Renal Dialysis / Q000009:adverse effects*
D006680:HLA Antigens; D005293:Ferritins; D007501:Iron; D000410:Alanine Transaminase; D003676:Deferoxamine